This website uses cookies
Read our Privacy policy and Terms of use for more information.
Dive into a collection of past posts and rediscover timeless content.
What the 37% rule really tells pharma about stopping rules, sunk costs, and the behavioural traps in between.
May 28, 2026
•
4 min read
Five ways survivorship bias shapes results in cost-effectiveness models, NMAs, and real-world comparators
May 19, 2026
Why I left Gilead, what Von Hein Consulting does, and what doesn't change for this newsletter.
May 11, 2026
2 min read
A new chief exec, a QALY debate that won't go away, and the moment NICE and the MHRA finally got in the same room.
Apr 6, 2026
5 min read
Grant Coren on hiring freezes, AI screening, ageism, and what it really takes to land a role in life sciences right now
Mar 30, 2026
6 min read
